Latest news with #Rathi
India Today
6 days ago
- Business
- India Today
Anthem Biosciences IPO to close for bidding today: Check latest subscription, GMP
The initial public offering (IPO) of Anthem Biosciences Ltd will close for subscription on Wednesday, July Rs 3,395 crore IPO has attracted strong interest from investors since it opened on July 14, especially in the high net-worth individual (HNI) and retail IPO is entirely an offer for sale (OFS) of 5.96 crore equity shares by existing shareholders. The company itself will not receive any money from this offer. The price band has been set at Rs 570 per STATUSAs of the end of Day 2, the IPO was subscribed 3.48 times. The retail investors' portion was booked 2.21 times, while the non-institutional investors' (NII) quota saw a strong response with 10.26 times the qualified institutional buyers (QIBs) have so far bid for only 0.62 times the reserved final subscription figures will be available once the bidding closes at the end of trading hours MARKET PREMIUMThe grey market premium (GMP) for Anthem Biosciences has been rising of July 16 (7:31 am), the latest GMP stood at Rs 156. With the upper price band of Rs 570, the estimated listing price is expected to be around Rs 726. This suggests a likely listing gain of 27.37%.Several brokerages have recommended subscribing to the IPO, citing the company's position in a high-growth segment and its strong financial track Securities said Anthem is well-positioned in the growing contract research, development, and manufacturing (CRDMO) industry. The brokerage pointed out the company's expansion plans, consistent profitability, and strong business pipeline. It called the IPO 'fairly priced' when compared with peers and advised investors to subscribe at the cut-off price for long-term Rathi also gave a 'Subscribe' rating. It highlighted Anthem's focus on specialty ingredients and peptides, backed by strong client relationships and a fee-for-service model that helps build long-term business. While the IPO's valuation appears high with a price-to-earnings (PE) ratio of 70.6 based on annualised FY25 earnings, the report said the business fundamentals justify the Shinde, research analyst at Mehta Equities, said the IPO offers investors a good chance to invest in a growing CRDMO space. He said Anthem has shown strong execution with more than 8,000 projects completed and 675 clients served. The company has also adopted advanced technologies and built a strong presence across both small and large molecule acknowledged that while the PE ratio of 70x may seem expensive, it is still lower than the industry average of 80x–90x. Given the company's consistent revenue growth and improving profit margins, the IPO still offers a fair entry point for long-term investors, he Biosciences reported a 34.3% jump in revenue in FY24 and followed that with another 30% increase in FY25. Net profit rose 22.9% in FY25 after a 4.6% dip in the previous company has also been able to maintain margins and continues to build a strong pipeline of over 240 active projects. Its focus on innovation, green chemistry, and complex drug development gives it an edge in a competitive for the IPO will close today, July 16. Share allotment is expected on July 17. The shares are likely to be listed on the BSE and NSE on July interested in subscribing should do so before market hours end today.(Disclaimer: The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)- Ends advertisement
India Today
7 days ago
- Business
- India Today
Anthem Biosciences IPO fully booked: Should you subscribe? Check listing gains
The initial public offering (IPO) of Anthem Biosciences Ltd is getting strong attention from investors as bidding enters its final offer, which opened for subscription on July 14, aims to raise Rs 3,395 crore through a complete offer for sale (OFS) of 5.96 crore equity of July 15 (1:54 PM), the IPO was subscribed 2.40 times overall. The retail category was booked 1.66 times, while non-institutional investors (NII) showed strong interest with 6.71 times subscription. However, qualified institutional buyers (QIBs) had only subscribed 0.48 times by that price band is fixed at Rs 570 per share. The offer is entirely an OFS, which means that the company will not receive any funds from the issue. Instead, existing shareholders are selling their MARKET PREMIUM (GMP)The grey market premium (GMP) for Anthem Biosciences IPO has increased steadily. On July 15, the GMP stood at Rs 124, which suggests an estimated listing price of Rs 694 per share. This means the IPO could offer a potential gain of 21.75% over the upper price Biosciences is a contract research, development, and manufacturing organisation (CRDMO) operating in both small and large molecule spaces. It has handled over 8,000 projects and has more than 675 clients. The company currently has 242 active projects and has adopted technologies like ADC, RNAi, flow chemistry and green chemistry early on, making it a niche player in the pharmaceutical and biotech company is known for its integrated services across drug discovery, development, and manufacturing, giving it an edge in a competitive industry. It has a strong R&D focus and globally compliant infrastructure, with more than 100 successful audits over the past three BROKERAGES SAYAccording to SBI Securities, Anthem Biosciences is well placed to benefit from the fast-growing CRDMO industry. They pointed to its planned capacity expansion, strong pipeline, and history of profitable growth. SBI noted that the IPO is fairly priced when compared to its peers and recommended investors to subscribe at the cut-off price for long-term Rathi also gave a 'SUBSCRIBE' rating. It highlighted the company's strong client relationships, innovative focus on specialty ingredients and peptides, and a differentiated fee-for-service model. The report mentioned the company's profitability and growth outlook, even though the asking price implies a price-to-earnings (PE) ratio of 70.6 times based on annualised FY25 Equities' research analyst Rajan Shinde said that the IPO gives investors a chance to invest in the high-growth CRDMO segment. He added that Anthem's integrated capabilities across molecules, early adoption of advanced technologies, and strong project pipeline make it a standout in the also pointed out that although the asking valuation of 70x seems high at first, it is still below the average industry range of 80x to 90x. This gives investors a fair entry point, especially considering the company's consistent revenue growth and profit revenue rose by 34.3% in FY24 and by 30% in FY25. Net profit also recovered, jumping 22.9% in FY25 after falling 4.6% the year for the IPO will close on July 16. The allotment is expected on July 17, and the listing is likely to happen on July 21 on both the NSE and The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)- Ends
Economic Times
14-07-2025
- Business
- Economic Times
Anthem Biosciences IPO opens for subscription. Should you bid?
Bengaluru's Anthem Biosciences has launched its IPO on July 14, closing on July 16. The IPO is entirely an offer for sale of Rs 3,395 crore. The company will list on NSE and BSE. Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band of Rs 540–570 per share, boasts integrated capabilities in both small and large molecules. Analysts recommend subscribing, citing its strong market position, revenue visibility, and high-margin business model. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Should You Subscribe? Anthem Biosciences, a Bengaluru-based contract research, development, and manufacturing organization (CRDMO), will open its initial public offering (IPO) on July 14. The issue, which closes on July 16, is entirely an offer for sale (OFS) of Rs 3,395 crore, with no fresh issue component. The company will be listed on both the NSE and price band for the IPO is set at Rs 540–570 per share, with a minimum lot size of 26 shares. Ahead of the issue opening, the GMP is around 18% over the issue priceFounded in 2006, Anthem Biosciences operates in a niche space within the pharma value chain—offering end-to-end drug discovery, development, and manufacturing services. It is one of the few Indian CRDMOs with integrated capabilities in both small molecules (chemical-based) and large molecules (biologics). The company's differentiated fee-for-service (FFS) model has helped it cater to small and mid-sized biotech firms globally, which make up a significant portion of its client has worked with over 675 clients and executed more than 8,000 projects since inception. It reported robust financials in FY25, with an EBITDA margin of 36.8% and Return on Net Worth (RoNW) of 20.8%. As of March 2025, its net worth stood at Rs 2,410 company's facilities are cGMP-compliant and have approvals from global regulatory bodies including USFDA, ANVISA, TGA, and PMDA. With an eye on scaling, it is expanding its fermentation and synthesis capacities to meet future demand from complex biologics and specialty Rathi and Canara Bank Securities have recommended a Subscribe rating for the issue. Analysts cite Anthem's strong industry positioning, robust revenue visibility, and high-margin business model as key IPO is priced at a P/E of 71x based on FY25 earnings, which is broadly in line with peers like Syngene (P/E ~51) and Divi's Labs (P/E 83). While valuation is on the higher side, analysts believe it's justified by the company's scale, technology edge, and consistent Anthem's differentiated offering in the high-growth CRDMO space, and its track record of innovation and global clientele, the IPO offers a long-term growth opportunity for investors.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Business Insider
14-07-2025
- Business
- Business Insider
Avenue Supermarts Ltd. (DMART) Receives a Sell from Morgan Stanley
In a report released today, Sheela Rathi from Morgan Stanley maintained a Sell rating on Avenue Supermarts Ltd., with a price target of INR3,350.00. The company's shares closed last Friday at INR4,069.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Rathi covers the Consumer Goods sector, focusing on stocks such as Hindustan Unilever Limited, Asian Paints Ltd., and Brainbees Solutions Limited. According to TipRanks, Rathi has an average return of -1.1% and a 43.48% success rate on recommended stocks. Currently, the analyst consensus on Avenue Supermarts Ltd. is a Hold with an average price target of INR4,380.63. Based on Avenue Supermarts Ltd.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR148.72 billion and a net profit of INR5.51 billion. In comparison, last year the company earned a revenue of INR127.27 billion and had a net profit of INR5.63 billion
The Hindu
27-06-2025
- Entertainment
- The Hindu
Behind Rural Modern Glass Studio's lighting collection, Vanaspati and Wishing Tree
The question that architect and lighting designer Arjun Rathi got asked the most at the recent Salone del Mobile was: 'Are you Indians manufacturing in Murano?' It was the first time that Indian blown glass was exhibited at the renowned Milan design week. Now, the two limited edition collections — Vanaspati and Wishing Tree — are back in India, and on display at Rathi's Rural Modern Glass Studio in Mumbai and at their lighting gallery at Eros Theatre. 'The Vanaspati collection is inspired by endangered species of flora and fauna from Indian forests,' says Rathi, who collaborated with artist Tejas Thackeray and the Thackeray Wildlife Foundation. 'We have pitcher plants [endangered in the Northeast because of ecosystem decimation], several kinds of wild flowers, and sweet lilies that are found in the eastern forests. Glass frogs and tiny metal creatures such as gold plated beetles, wasps, and bees, cast by an artist from Jaipur, have also been fused onto the lights.' The Wishing Tree collection, on the other hand, looks to the banyan tree — and the wishes that people make as they walk around it in temples across the length and breadth of the country. 'All the textures were created by taking real banyan roots and burning them into the glass,' shares the designer. The two collections mark the studio's first attempt at mixing two faculties of glass: flameworking (shaping glass using a torch to melt the material) and blown glass. 'We are also experimenting with so many colours for the first time, from reds and pinks to blues, greens and yellows. Compatibility is a big challenge in glass making,' Rathi adds. With 15 editions of each design, the collection is priced between ₹3.5 lakh and ₹12 lakh. Details:
